Request Demo
Last update 12 May 2025
MMH-MAP
Last update 12 May 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms Prospecta |
Target- |
Action- |
Mechanism- |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
3
Clinical Trials associated with MMH-MAPEUCTR2021-002366-41-IT
Phase II, multicenter, randomized, open-label study with MAP +/- denosumab regimen for the treatment of patients with metastatic osteosarcoma - AIEOP-ISG OsM+
NCT04295681
A Multicenter, Double-blind, Randomized, Parallel Group Placebo-controlled Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Cognitive Disorders in Patients With Ischemic Stroke in the Carotid Arteries
NCT03815292
Multicenter Double-blind Placebo-controlled Randomized Parallel-group Clinical Study of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Subjects in Early Rehabilitation Period of Ischemic Stroke
100 Clinical Results associated with MMH-MAP
Login to view more data
100 Translational Medicine associated with MMH-MAP
Login to view more data
100 Patents (Medical) associated with MMH-MAP
Login to view more data
1
Literatures (Medical) associated with MMH-MAP01 Jan 2021Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
Therapy of moderate cognitive impairment in the early recovery period of ischemic stroke
Article
Author: Voznyuk, I A ; Kurushina, O V ; Bogdanov, E I ; Kamchatnov, P R ; Zhadnov, V A ; Belova, A N ; Maslova, N N
100 Deals associated with MMH-MAP
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Ischemic stroke | Phase 3 | Russia | 19 Oct 2018 | |
| Mild cognitive disorder | Phase 3 | Russia | 19 Oct 2018 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 3 | 246 | (MMH-MAP) | tmxajjgdoa(wrqmdhtzdl) = osgxfqrwng cmqhglvhyv (cptkpdkreo, 3.5) View more | - | 28 Oct 2024 | ||
Placebo (Placebo) | tmxajjgdoa(wrqmdhtzdl) = ujhzjhranx cmqhglvhyv (cptkpdkreo, 2.4) View more | ||||||
Phase 3 | 276 | (MMH-MAP) | scocgicqjd = bqffcijtyo pmzwqrguna (vjnqxoscux, dgcptjyrye - uhrmumhsmq) View more | - | 23 Feb 2021 | ||
Placebo (Placebo) | scocgicqjd = rjzybmjina pmzwqrguna (vjnqxoscux, rntxjwqmpi - hzfavjsnct) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free